Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout

Charles Arber1, Claudio Villegas-Llerena1,2, Jamie Toombs1,3, Jennifer M. Pocock2, Natalie S. Ryan4, Nick C. Fox1,3,4, Henrik Zetterberg1,3,5,6, John Hardy1,3 and Selina Wray1

1Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
2Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK
3UK Dementia Research Institute at UCL, London, UK
4Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
6Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Correspondence to be addressed to: selina.wray@ucl.ac.uk
UCL Queen Square Institute of Neurology, Department of Neurodegenerative Disease, 1 Wakefield Street, London WC1N 1PJ, UK

Running title: PSEN1 intr4del allelic series in iPSC-neurons

Abstract

Mutations in presenilin-1 (PSEN1), encoding the catalytic subunit of the amyloid precursor protein-processing enzyme γ-secretase, cause familial Alzheimer’s disease. However, the mechanism of disease is yet to be fully understood and it remains contentious whether mutations exert their effects predominantly through gain or loss of function. To address this question, we generated an isogenic allelic series for the PSEN1 mutation intron 4 deletion; represented by control, heterozygous and homozygous mutant induced pluripotent stem cells in addition to a presenilin-1 knockout line. Induced pluripotent stem cell-derived cortical neurons reveal reduced, yet detectable amyloid-beta levels in the presenilin-1 knockout line, and a mutant gene dosage-dependent defect in amyloid precursor protein processing in PSEN1 intron 4 deletion lines, consistent with reduced processivity of γ-secretase. The different effects of presenilin-1 knockout and the PSEN1 intron 4 deletion mutation on amyloid precursor protein-C99 fragment accumulation, nicastrin maturation and amyloid-beta peptide generation support distinct consequences of familial Alzheimer’s disease-associated mutations and knockout of presenilin-1 on the function of γ-secretase.

Keywords
Alzheimer’s disease, iPSCs, CRISPR/Cas9, amyloid beta

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aβ</td>
<td>amyloid beta</td>
</tr>
<tr>
<td>APP</td>
<td>amyloid precursor protein</td>
</tr>
<tr>
<td>CRISPR</td>
<td>clustered regularly interspersed short palindromic repeats</td>
</tr>
<tr>
<td>DAPT</td>
<td>γ-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester</td>
</tr>
<tr>
<td>fAD</td>
<td>familial Alzheimer’s disease</td>
</tr>
<tr>
<td>iPSC</td>
<td>induced pluripotent stem cell</td>
</tr>
<tr>
<td>NCSTN</td>
<td>nicastrin</td>
</tr>
<tr>
<td>PSEN1/2</td>
<td>presenilin-1 or presenilin-2</td>
</tr>
<tr>
<td>RFLP</td>
<td>restriction fragment length polymorphism</td>
</tr>
<tr>
<td>sgRNA</td>
<td>single guide RNA</td>
</tr>
<tr>
<td>ssODN</td>
<td>single stranded oligodeoxynucleotide</td>
</tr>
</tbody>
</table>
Introduction

Amyloid precursor protein (APP) is cleaved by $\gamma$-secretase, the catalytic subunit of which consists of presenilin-1 (PSEN1) or presenilin-2 (PSEN2), to produce amyloid $\beta$ (A$\beta$). Mutations in APP and PSEN1/2 that cause familial Alzheimer’s disease (fAD) are believed to alter this interaction, increasing the relative proportion of aggregation-prone A$\beta$ species (Ryan et al., 2016), and forming the basis of the amyloid cascade hypothesis (Hardy and Allsop, 1991).

PSEN1 and PSEN2 are alternate catalytic subunits of $\gamma$-secretase, a tetrameric protein complex also containing nicastrin (NCSTN), PSEN enhancer (PEN2) and alternate subunits anterior pharynx 1a/b (APH1a/b) (De Strooper, 2003). $\gamma$-Secretase serves as a membrane protease, cleaving numerous substrates (Haapasalo and Kovacs, 2011) that include the products of $\beta$-secretase and $\alpha$-secretase cleavage of APP (C99 and C83 respectively). Cleavage of C99 by $\gamma$-secretase occurs through an initial endopeptidase-like activity followed by subsequent carboxypeptidase-like cleavages to generate shorter A$\beta$ fragments (Takami et al., 2009; Matsumura et al., 2014). In addition, $\gamma$-secretase-independent activities for PSEN1 have been described, such as a chaperone activity crucial for the glycosylation and maturation of NCSTN (Leem et al., 2002).

PSEN1 mutations have been shown to consistently reduce the carboxypeptidase-like activity of $\gamma$-secretase, leading to the accumulation of longer, more amyloidogenic A$\beta$ species, such as A$\beta$42 and A$\beta$43 (Chávez-Gutiérrez et al., 2012; Szaruga et al., 2015; Arber et al., 2019). This can be evidenced as an increased A$\beta$42:38 ratio (Takami et al., 2009; Matsumura et al., 2014). The PSEN1 intron 4 deletion mutation (L113_I114insT; hereafter referred to as int4del) describes the deletion of a guanine nucleotide in the splice donor region of PSEN1 after exon 4 leading to three alternative transcripts; one coding a full length protein with an insertion of an additional threonine in the PSEN1 protein, and two shorter transcripts with premature stop codons (De Jonghe et al., 1999). The long transcript was shown to be responsible for elevated A$\beta$42 generation (De Jonghe et al., 1999). We and others have previously shown that this mutation increases the A$\beta$42:38 ratio in patient derived iPSC-neurons, and potentially reduces overall $\gamma$-secretase activity (Moore et al., 2015; Arber et al., 2019).
There has been contention over the question of whether mutant \textit{PSEN1} alleles confer predominantly gain or loss-of-function (Veugelen \textit{et al.}, 2016; Xia, Kelleher and Shen, 2016). In order to further investigate the molecular mechanisms of the \textit{PSEN1} int4del mutation in a human neuronal system, we used CRISPR/Cas9 gene editing to produce an isogenic allelic series from patient-derived iPSCs. The series is represented by isogenic control (wild type) cells, heterozygous and homozygous mutation bearing cells, as well as \textit{PSEN1} knockout cells. We find that iPSC-derived cortical neurons maintain Aβ generation in \textit{PSEN1} knockout cells and display a mutant gene dosage-dependent phenotype on APP/Aβ processing and Aβ42 generation. The data support distinct effects of fAD-associated mutations and \textit{PSEN1} protein knockout.
Materials and Methods

Cell Culture

The acquisition of patient fibroblasts for the generation of iPSC was approved by the National Hospital for Neurology and Neurosurgery and Institute of Neurology Joint Research Ethics Committee (Study Title: Induced pluripotent stem cells derived from patients with familial Alzheimer's disease and other dementias as novel cell models for neurodegeneration, Reference: 09/H0716/64).

All reagents are from ThermoFisher unless specified. PSEN1 int4del iPSCs were obtained from StemBancc and cultured in Essential 8 media on Geltrex substrate and passaged using 0.5mM EDTA, with the exception of gene editing steps that were performed in mTESR media (Stem Cell Technologies). Differentiation was performed following published protocols (Shi et al., 2012). Briefly, iPSCs were grown to confluency and switched to N2B27 media containing 10μM SB431542 and 1μM dorsomorphin (both Tocris). N2B27 media is composed of a mix of 1:1 DMEM-F12 and Neurobasal supplemented with 0.5x N2 supplement, 0.5x B27 supplement, 0.5x non-essential amino acids, 1mM L-glutamine, 25U pen/strep, 10μM β-mercaptoethanol and 25U insulin. Following 10 days of neural induction, cells were maintained in N2B27 without SB431542 and dorsomorphin until day 100, which was taken as the final time point for neuronal analysis. DAPT (Tocris) treatment was performed with 10μM DAPT for 48 hours.

Karyotype Analysis

Genomic DNA from iPSC lines was tested using the hPSC Genetic Analysis Test (Stem Cell Technologies). Analysis of the eight most common PSC mutation sites showed there was no significant chromosomal abnormalities in the four iPSC lines. Results highlight possible, non-significant abnormalities that are believed to be qPCR artefacts.

CRISPR/Cas9-Mediated Genome Editing

sgRNAs were designed and constructed using the CRISPR finder tool from the WTSI Genome Editing (WGE) website (Hodgkins et al., 2015). The single-stranded donor oligonucleotide (ssODN, Table 1), used as homologous recombinant template, was designed to correct the int4del mutation in the heterozygous patient cells. ssODN was asymmetric (60bp and 35bp to the to the 5’ and 3’ends of the double strand break, respectively) and was synthesized with phosphorothioate modifications (IDT) to increase the efficiency of homology directed DNA
repair (Renaud et al., 2016). For CRISPR/Cas9 gene editing, we used the RNP (ribonucleoprotein) delivery strategy. RNP preparation was performed as per the manufacturer’s protocol using the Alt-R™ CRISPR tracrRNA, crRNA and S.p. Cas9 Nuclease 3NLS (IDT). Both the ssODN and the RNP were delivered simultaneously into patient derived iPSCs by electroporation (Amaxa 4D, Lonza). Transfected cells were seeded and expanded in mTesr media + 10µm ROCK inhibitor (StemCell Technologies). Screening of modified clones was performed by restriction fragment length polymorphism (RFLP) using the RsaI enzyme, which specifically cleaves the WT and not the int4del pathogenic allele. Edited clones were confirmed by PCR and Sanger sequencing. Off-target sites were predicted using the CRISPR finder tool and the sgRNA sequence used for gene editing. PCR primers were designed for the amplification of the top-5 potential off-target sites (Table 1). Sanger sequencing screening of our isogenic allelic series of iPSC cells, showed no evidence of off-target activity at any of the screened loci. Sequence alignment was performed using SnapGene software and chromatograms with frame shift mutations were deconvoluted using the Indigo program (gear.embl.de/indigo/).

Immunocytochemistry
Cells were fixed for 15 minutes in 4% paraformaldehyde. Following fixation, cells were washed 3 times in PBS with 0.3% Triton-X-100 (PBST) and blocked in 3% bovine serum albumin in PBST for 20 minutes. Primary antibodies (Table 2) were added to cells overnight at 4°C in blocking solution. Cells were washed 3 times in PBST and Alexafluor secondary antibodies were added in blocking solution for 1 hour at room temperature. Following three final washes in PBST (the first of which contained DAPI nuclear counterstain), cells were mounted in fluorescence mounting media (DAKO) and imaged on a Zeiss LSM microscope.

PCR
RNA was isolated from neurons using Trizol reagent following the manufacturer’s protocols. cDNA was generated using superscript IV following the manufacturers protocols with 2µg of total RNA and using random hexamer primers. PCR was performed using GoTaq PCR mastermix (Promega). Quantitative PCR was performed using Power SYBR green and an MX3000P thermocycler (Agilent). Primers are shown in Table 1.

Western Blotting
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors (Roche). Lysates were denatured in NuPage LDS buffer and loaded onto 4-12% precast polyacrylamide gels in MES running buffer (NuPage/ThermoFisher). Proteins were transferred to a nitrocellulose membrane, blocked in 3% bovine serum albumin and blotted using antibodies in Table 2. Images were taken and analysed on an Odyssey Fc (LiCor Biosciences).

**Aβ Electrochemiluminescence**

48 hour-conditioned media were collected from neuronal cultures and centrifuged to remove cell debris. Aβ42, Aβ40 and Aβ38 were quantified simultaneously using the Meso Scale Discovery V-Plex Aβ peptide panel kit (6E10) by electrochemiluminescence. Samples were diluted 1:1 with diluent 35 and measurements were made on the MSD Sector 6000. Aβ concentrations in the cell media were normalised to cell pellet protein concentration, measured using BioRad BCA assay.

<table>
<thead>
<tr>
<th>Table 1. Primers used in this study.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assay</strong></td>
</tr>
<tr>
<td>PSEN1 int4del specific</td>
</tr>
<tr>
<td>PSEN1 exon 4 splicing</td>
</tr>
<tr>
<td>PSEN1</td>
</tr>
<tr>
<td>ssODN</td>
</tr>
<tr>
<td>sgRNA</td>
</tr>
<tr>
<td>Off Target 1</td>
</tr>
<tr>
<td>Off Target 2</td>
</tr>
<tr>
<td>Off Target 3</td>
</tr>
<tr>
<td>Off Target 4</td>
</tr>
<tr>
<td>Off Target 5</td>
</tr>
<tr>
<td>RPL18a</td>
</tr>
<tr>
<td>APP</td>
</tr>
<tr>
<td>PSEN1</td>
</tr>
<tr>
<td>PSEN2</td>
</tr>
<tr>
<td>BACE1</td>
</tr>
<tr>
<td>TUBB3</td>
</tr>
<tr>
<td>TBR1</td>
</tr>
<tr>
<td>CTIP2</td>
</tr>
<tr>
<td>ECE1</td>
</tr>
<tr>
<td>ACE</td>
</tr>
<tr>
<td>IDE</td>
</tr>
<tr>
<td>NEP</td>
</tr>
</tbody>
</table>

(*) phosphorothioate modification
Table 2. Antibodies used in this study.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Company</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSEA4</td>
<td>Biolegend MC-813–70</td>
<td>Mouse</td>
</tr>
<tr>
<td>OCT4</td>
<td>SantaCruz sc5297</td>
<td>Goat</td>
</tr>
<tr>
<td>TUJ1</td>
<td>Biolegend 801201 and 802001</td>
<td>Mouse and Rabbit</td>
</tr>
<tr>
<td>TBR1</td>
<td>Abcam ab31940</td>
<td>Rabbit</td>
</tr>
<tr>
<td>APP 6e10</td>
<td>Biolegend 803014</td>
<td>Mouse</td>
</tr>
<tr>
<td>APP C-term</td>
<td>Biolegend 802803</td>
<td>Mouse</td>
</tr>
<tr>
<td>PSEN1 N-term</td>
<td>Millipore MAB1563</td>
<td>Rat</td>
</tr>
<tr>
<td>PSEN1 C-term</td>
<td>Millipore MAB5232</td>
<td>Mouse</td>
</tr>
<tr>
<td>PSEN2</td>
<td>Cell Signaling Technologies 9979</td>
<td>Rabbit</td>
</tr>
<tr>
<td>NCSTN</td>
<td>BD Transduction Labs 612290</td>
<td>Mouse</td>
</tr>
<tr>
<td>Actin</td>
<td>Sigma 1978</td>
<td>Mouse</td>
</tr>
</tbody>
</table>
Statistical analysis

Data analysis was performed in Microsoft Excel and GraphPad Prism 7. Samples were compared via one-way ANOVA with subsequent post-hoc Tukey’s multiple comparisons test. * P>0.05, ** P>0.01, *** P>0.001, ****P>0.0001. Error bars on histograms show +/- standard deviation of the mean and independent experimental replicates are shown via numbers within histograms.

Data availability

The authors confirm that all the data supporting the findings of this study are available within the article and readily available upon request. For ANOVA analyses, exact P values, F values and degrees of freedom are presented in the supplementary material.
Results

Generation of PSEN1 int4del allelic series
CRISPR/Cas9 gene editing was used to generate an isogenic series of iPSC lines from a patient-derived PSEN1 int4del iPSC line (Fig 1). In order to generate an allelic series, a PAM site 6 base pairs upstream of the mutation was selected, recognising both mutant and wild type alleles. This enables both homology-directed repair from the ssODN (single-stranded oligodeoxynucleotide) and template-free repair of the pathogenic variant in the same CRISPR/Cas9 transfection (Shen et al., 2018). For increased efficiency of homology-directed DNA repair, the ssODN template was modified to contain phosphorothioate moieties (Renaud et al., 2016).

Following an initial screen of 800 iPSC colonies by restriction fragment length polymorphism (see methods section), Sanger sequencing was used to confirm the generation of; 1) an isogenic control cell line, 2) an unedited line, 3) a homozygous int4del line, and 4) a PSEN1 knockout line (Fig 2A). The knockout line was a compound heterozygous, which contained a 4 and a 25 base pair deletion; each leading to a reading frame shift (Fig S1). The allelic series was screened and found to be free from off-target nucleotide changes at 5 most likely genomic sites (see methods section) and pluripotency was confirmed via the expression of OCT4 and SSEA4 (Fig 2B). Karyotype stability was tested and no significant aberrations were found (Fig S2).

iPSCs were subjected to cortical differentiation, generating the cell type affected by fAD (Shi et al., 2012). All lines generated neurons with a similar efficiency, as evidenced by the expression of the deep layer cortical marker TBR1 by immunocytochemistry and the population expression level of TUBB3, TBR1 and CTIP2 by qPCR (Fig 2C-D). Finally, to confirm the mutation status of the iPSC-derived neurons, cDNA was analysed by PCR to depict aberrant splicing of PSEN1 in mutation-bearing neurons (Fig 2E) (Tysoe et al., 1998). In addition to the full length L113_I114insT encoding transcript (374bp), heterozygous and homozygous PSEN1 int4del lines show evidence of one short transcript produced by aberrant splicing (193bp).

iPSC-derived PSEN1 knockout neurons display aberrant APP-processing
Using primers 3’ to the site of gene editing, qPCR analysis showed reduced PSEN1 expression in the knockout cell line (Fig 3A). Interestingly, PSEN2 showed similar expression in all cell
lines, suggesting that loss of PSEN1 does not result in compensation by upregulation of this alternate $\gamma$-secretase subunit. Expression of APP and BACE1 was not significantly altered based on mutation status.

At the protein level, the expected absence of PSEN1 protein was confirmed in the knockout line (using antibodies that recognise the N- or C-terminus of PSEN1) (Fig 3B). The PSEN1 knockout line also showed a reduced maturation of NCSTN, evidenced as a relative lack of the larger band that represents the glycosylated protein (Leem et al., 2002). This phenotype was not seen in lines containing the mutation (Fig 3C). Similar to qPCR analysis, there was no apparent compensatory upregulation of PSEN2 protein in PSEN1 knockout cells as analysed by western blot (Fig 3D). Total APP levels were largely equivalent (Fig 3E-F), however an accumulation of a fragment predicted to be C99 was present in the PSEN1 knockout neurons – analogous to $\gamma$-secretase-inhibited wild-type cells (Fig 3E).

**Aβ is produced in knockout cells and disease-associated processing defects are dependent on mutant gene dosage**

To investigate the molecular effects of the PSEN1 int4del mutation, we analysed the Aβ profiles of the neuronal condition media 100 days post neural induction. PSEN1 knockout cells produced less Aβ compared with other lines, reaching significance for Aβ38 (Fig 4A-C). The levels of Aβ remained within detection limits, which is in contrast to neurons treated with the $\gamma$-secretase-inhibitor DAPT, where Aβ was at or below the detection threshold. Expression of four Aβ degrading enzymes remains consistent between genotypes (Fig S3), suggesting that the detection of Aβ is not a result of reduced degradation.

Knockout cells produced a non-significant increase in the Aβ42:40 and Aβ42:38 ratios and a significantly reduced Aβ38:40 ratio when compared to isogenic control cells (Fig 4D-F). These changes are analogous to the changes witnessed between the wild type and the heterozygous int4del line.

The heterozygous and homozygous int4del lines showed increased total levels of Aβ42 and reduced production of Aβ38 in a gene dosage-dependent manner (Fig 4A-C). This corresponds to similar stepwise mutant gene dosage-dependent changes to Aβ42:40, Aβ42:38 and Aβ38:40.
(Fig 4D-F). In each instance, the homozygous line was significantly different from the patient-derived heterozygous line.
Discussion
We successfully generated an isogenic allelic series of the PSEN1 mutation int4del with which to investigate the molecular mechanisms of fAD mutation-dependent effects on APP processing. We found that PSEN1 knockout cells produce low levels of Aβ and that PSEN1 int4del heterozygous and homozygous cells produce a stepwise increase in longer, disease-associated Aβ peptides.

It is intriguing that PSEN1 knockout neurons produce small amounts of Aβ. This is in contrast to γ-secretase inhibited cells where Aβ species are often below the detection limit, but in agreement with the detection of around one fifth of total Aβ levels in mouse PSEN1 knockout primary neurons (De Strooper et al., 1998). It is noteworthy that Aβ is barely detectable after γ-secretase administration to patients during clinical trials (Gillman et al., 2010). We provide evidence for no compensatory upregulation of PSEN2 at either the transcriptional or protein level, which could potentially be due to alternate subcellular compartmentalisation (Sannerud et al., 2016). These data suggest that PSEN2 may produce low levels of Aβ in neurons. Alternatively, the lack of compensation by PSEN2 in PSEN1 knockout neurons, taken together with the reduced functional γ-secretase pool, seen via NCSTN immaturity, promotes the hypothesis that alternative Aβ-generating enzymes are contributing to Aβ production in PSEN1 knockout human neurons. This hypothesis is reinforced as Aβ is detectable in PSEN1 and PSEN2 double knockout mice (Wilson et al., 2002). It should be noted that in non-neuronal cells, knockout of either PSEN1 or PSEN2 does not alter total Aβ generation, whereas double knockout drastically reduces total Aβ (Lessard et al., 2019). Candidates for C-terminal Aβ degrading activity include matrix metalloproteinase 2 or 9 (MMP2/9) (Hernandez-Guillamon et al., 2015) and cathepsin B (Mueller-Steiner et al., 2006).

The finding that PSEN1 knockout cells have a relative increase in Aβ42 compared with Aβ38 means that variability in PSEN1 expression levels could contribute to altered Aβ profiles in AD.

It is important that int4del homozygous cells display an additional, stepwise increase in disease-associated Aβ profiles compared with the patient-derived lines. This equates to a linear increase in total Aβ42 production. Our data demonstrate a mutant gene dosage-dependent
effect in Aβ42 generation reinforcing similar findings with the PSEN1 exon 9 mutation (Woodruff et al., 2013), the PSEN1 M146I mutation (Paquet et al., 2016) and recently 7 fAD mutations investigated by genome editing (Kwart et al., 2019). The PSEN1 knockout neurons and mutation-bearing neurons show different phenotypes with respect to quantitative production of Aβ and, taken together with the dissimilar effects on C99 accumulation and NCSTN maturation, these data argue against a simple loss-of-function mechanism for PSEN1 mutations. In agreement with these findings and in contrast to fAD-causing mutations, PSEN1 loss-of-function mutations have been found to cause acne inversa rather than dementia (Wang et al., 2010).

The fact that PSEN1 int4del homozygosity does not lead to altered NCSTN maturation, suggests that the effect of the mutation acts on γ-secretase as a whole and not on the activity of PSEN1 itself. This is reinforced by recent crystal structure findings (Yang et al., 2019; Zhou et al., 2019) and mechanistic studies (Szaruga et al., 2017; Petit et al., 2019) whereby fAD mutations appear to destabilise substrate to holo-enzyme complex interaction to release longer Aβ fragments before complete enzymatic processing, rather than altering the PSEN1 subunit activity.

The fact that APP protein is significantly increased in the isogenic control compared with the parental PSEN1 int4del heterozygous line is intriguing. In our previous work, total APP is not significantly altered in the patient-derived line versus unrelated controls (Arber et al., 2019). We believe the slight increase in APP total levels in the corrected line may directly relate to the correction of the mutation.

In conclusion, data from this isogenic human neuronal allelic series reinforce the findings that fAD-associated mutations in PSEN1 lead to accumulation of Aβ by reducing the processivity of APP by γ-secretase. Mutations reduce carboxypeptidase-like activity, releasing longer amyloidogenic Aβ peptides in a gene dose-dependent manner. PSEN1 knockout cells generate Aβ and also show distinct substrate processing alterations from int4del homozygous cells, potentially separating γ-secretase-dependent and independent functions of PSEN1 and arguing against a simple loss-of-function mechanism. These findings support a destabilisation of γ-secretase-substrate interaction by the mutation; information that is valuable for the design of novel therapeutics.
Acknowledgements
We would like to thank the research participants for their time and involvement in the research and Mr Jamie Mitchell for rescuing a crucial vial of cells.

Funding
This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre. The work was also partly supported by the UK Dementia Research Institute at UCL.

CA is supported by a fellowship from the Alzheimer’s Society (AS-JF-18-008) and SW is supported by an Alzheimer’s Research UK Senior Research Fellowship (ARUK-SRF2016B-2). NSR is supported by a University of London Chadburn Academic Clinical Lectureship in Medicine. NCF acknowledges the support of the UK Dementia Research Institute at UCL.

This work was also supported by the UK Medical Research Council funding to the MRC Dementia Platform UK (MR/M02492X/1) and Medical Research Council core funding to the High-Content Biology Platform at the MRC-UCL LMCB university unit (MC_U12266B).

Competing Interests
The authors have no competing interests to declare.
References


Figure Legends

Figure 1. Scheme for the gene editing of patient-derived PSEN1 int4del iPSCs
A) Strategy for the generation of isogenic cells using CRISPR/Cas9-editing of an iPSC line from an individual carrying the PSEN1 int4del mutation.
B) Genomic positioning of the editing site, showing ssODN repair arm (purple), mutation site (purple) and sgRNA (green) with PAM site (red). sgRNA (single guide RNA, for CRISPR/Cas9 targeting); RFLP (restriction fragment length polymorphism, used for screening); ssODN (single stranded oligodeoxynucleotide, for homology directed repair).

Figure 2. Characterisation of gene-edited iPSC and neurons
A) Sanger sequencing was used to confirm the generation of a PSEN1 knockout (i), a corrected wildtype PSEN1 line (ii), an unedited heterozygous mutant line (ii) and a homozygous PSEN1 int4del mutation line (iv).
B) Immunocytochemistry was performed on all iPSC lines following CRISPR/Cas9 editing to confirm pluripotency with the pluripotency markers OCT4 (red) and SSEA4 (green). Scale bar 100 μm.
C) Successful differentiation of iPSC into neurons was characterised 50 days post induction by immunocytochemistry for the neuronal marker TUJ1 (red) and deep layer cortical neuronal marker TBR1 (green). Scale bar 25 μm.
D) Further characterisation of cortical differentiation was performed using qPCR analysis 100 days post neural induction to assess expression of neuronal marker TUBB3, and cortical layer markers TBR1 and CTIP2. Numbers within histogram represent the number of independent neural inductions.
E) PCR analysis of PSEN1 splicing in cDNA from day 100 neurons using primers recognising exons 3 and 5 of PSEN1 mRNA. The full length transcript is depicted at 374bp and one short transcript caused by aberrant splicing is evident at 193bp in mutation bearing neurons (we do not see evidence of a second aberrantly spliced band at 111bp).

Figure 3. Analysis of γ-secretase and APP processing in iPSC-derived neurons
A) PSEN1, PSEN2, APP and BACE1 expression in iPSC-derived neurons 100 days post induction was assessed by qPCR in neurons from PSEN1 knockout, PSEN1 wildtype, PSEN1 int4del heterozygous and PSEN1 int4del homozygous lines. PSEN1 expression was significantly reduced in the PSEN1 knockout neurons. No significant differences in PSEN2, APP and BACE1 were observed.
B-E) Western blot on whole cell lysates of day 100 neurons was used to analyse protein levels of PSEN1 N-terminal fragments (28kDa), PSEN1 C-terminal fragments (18kDa), NCSTN (100kDa), PSEN2 C-terminal fragments (18kDa), APP (100kDa) and neuronal marker TUJ1 (50kDa). The DAPT sample represents an unrelated control line treated with the γ-secretase inhibitor DAPT at 10μM for 48 hours.
F) Quantification of western blot band intensities in B-E. PSEN1 protein abundance is significantly reduced in PSEN1 knockout lysates and APP is significantly increased in the corrected wildtype neurons compared with parental PSEN1 int4del.
* P<0.05, ** P<0.01, *** P<0.001 by one way ANOVA with Tukey’s post hoc analysis. Numbers within histograms represent the number of independent neural inductions.

Figure 4. Aβ analysis in iPSC-neuronal-conditioned media
A-C) Quantification of Aβ38, Aβ40 and Aβ42 in 48 hour-conditioned media from neurons at day 100, measured by electrochemiluminescence and normalised to total protein content from the cell pellet. The DAPT sample is a representative unrelated control line treated with 10μM of the γ-secretase inhibitor DAPT for 48 hours, n.d. – not detected. Numbers within histograms represent the number of independent neural inductions.

D-F) Aβ ratios to depict the disease associated Aβ42:40 ratio, γ-secretase carboxypeptidase-like activity Aβ42:38 and endopeptidase cleavage position choice Aβ38:40. n=3 for each sample apart from where Aβ38 was below detection limit for one null/null sample. Green bars represent non-AD neuronal ratios from Arber et. al. 2019.

* P>0.05, ** P>0.01, *** P>0.001, ****P>0.0001 by one way ANOVA with Tukey’s post hoc analysis.
Fig 1.

338x190mm (225 x 225 DPI)
Fig 2.

338x190mm (225 x 225 DPI)
Fig 3.

338x190mm (225 x 225 DPI)
Fig 4.

338x190mm (225 x 225 DPI)
We report the generation of an allelic, isogenic series for the familial Alzheimer’s disease mutation PSEN1 int4del as well as total PSEN1 knockout. Aβ profiles follow a mutation dose-dependent pattern. PSEN1 knockout lines display distinct phenotypes from int4del lines, including reduced mature nicastrin, arguing against a simple loss of function mechanism for fAD mutations.